- Home
- APLT vs BUUU Comparison
APLT vs BUUU Comparison
Compare APLT & BUUU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLT
- BUUU
- Stock Information
- Founded
- APLT 2016
- BUUU 2017
- Country
- APLT United States
- BUUU Hong Kong
- Employees
- APLT N/A
- BUUU N/A
- Industry
- APLT Biotechnology: Pharmaceutical Preparations
- BUUU Services-Misc. Amusement & Recreation
- Sector
- APLT Health Care
- BUUU Consumer Discretionary
- Exchange
- APLT Nasdaq
- BUUU Nasdaq
- Market Cap
- APLT 63.6M
- BUUU 68.1M
- IPO Year
- APLT 2019
- BUUU 2025
- Fundamental
- Price
- APLT $0.41
- BUUU $7.86
- Analyst Decision
- APLT Buy
- BUUU
- Analyst Count
- APLT 6
- BUUU 0
- Target Price
- APLT $6.10
- BUUU N/A
- AVG Volume (30 Days)
- APLT 771.9K
- BUUU 81.8K
- Earning Date
- APLT 11-06-2025
- BUUU 01-01-0001
- Dividend Yield
- APLT N/A
- BUUU N/A
- EPS Growth
- APLT N/A
- BUUU N/A
- EPS
- APLT N/A
- BUUU 0.04
- Revenue
- APLT $121,000.00
- BUUU $5,754,120.00
- Revenue This Year
- APLT N/A
- BUUU N/A
- Revenue Next Year
- APLT $5,931.24
- BUUU N/A
- P/E Ratio
- APLT N/A
- BUUU $210.68
- Revenue Growth
- APLT N/A
- BUUU 64.23
- 52 Week Low
- APLT $0.30
- BUUU $3.67
- 52 Week High
- APLT $10.62
- BUUU $9.50
- Technical
- Relative Strength Index (RSI)
- APLT 38.50
- BUUU N/A
- Support Level
- APLT $0.40
- BUUU N/A
- Resistance Level
- APLT $0.46
- BUUU N/A
- Average True Range (ATR)
- APLT 0.03
- BUUU 0.00
- MACD
- APLT -0.01
- BUUU 0.00
- Stochastic Oscillator
- APLT 7.74
- BUUU 0.00
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.